How Pharma's CEO Pay Packages Measure Up
Since I’ve just spend close to a half-hour flipping through Big Pharma proxy filings, I figured I’d take just a little longer and put together a quick table of the best-paid chief executives in pharma and biotech. Enjoy.
The following data is all taken from 2007 proxy statements issued by the industry’s largest U.S. companies; I’ve linked to the proxies in the following list. (I’d have included European pharmas as well, but they don’t appear to file proxies in the U.S.)
- Miles White, Abbott Laboratories: $33.3 million (proxy)
- William Weldon, Johnson & Johnson: $31.9 million (proxy)
- Fred Hassan, Schering-Plough: $30.3 million (proxy)
- Kevin Sharer, Amgen: $19.9 million (proxy)
- Richard Clark, Merck: $19.9 million (proxy)
- Arthur Levinson, Genentech: $18.2 million (proxy)
- Henri Termeer, Genzyme: $14.6 million (proxy)
- Sidney Taurel, Eli Lilly: $13.0 million (proxy)
- Bernard Poussot, Wyeth: $12.7 million (proxy)
- James Cornelius, Bristol-Myers Squibb: $11.3 million (proxy)
- John Martin, Gilead Sciences: $10.8 million (proxy)
- Jeffrey Kindler, Pfizer: $9.5 million (proxy)
- James Mullen, Biogen Idec: $9.0 million (proxy)
(Image by Flickr user velo_city, CC 2.0)
A 14-year veteran of the Wall Street Journal, David P. Hamilton is BNET's Industries editor. Prior to coming to BNET, David founded the LifeScience section of VentureBeat, a news site for the innovation and venture business.
BNET User Analysis